These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 2660764

  • 21. Early and late surfactant treatments in baboon model of hyaline membrane disease.
    Maeta H, Vidyasagar D, Raju TN, Bhat R, Matsuda H.
    Pediatrics; 1988 Feb; 81(2):277-83. PubMed ID: 3340477
    [Abstract] [Full Text] [Related]

  • 22. A model of the effect of surfactant treatment on gas exchange in hyaline membrane disease.
    Cotton RB.
    Semin Perinatol; 1994 Feb; 18(1):19-22. PubMed ID: 8209282
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The effectiveness and cost of exogenous pulmonary surfactant replacement therapy.
    Smith J, Pieper C, Gie RP.
    S Afr Med J; 1995 Nov; 85(11):1192, 1195-6. PubMed ID: 8597017
    [No Abstract] [Full Text] [Related]

  • 27. [Importance of surface active substances in the lung].
    Kadlec K, Kandus J.
    Vnitr Lek; 1972 Jun; 18(6):521-31. PubMed ID: 5068058
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Unilateral pulmonary interstitial emphysema and treatment with colfosceril palmitate.
    Abrahamson EL, Viswanath M, Kovar IZ, Jawad SA.
    Lancet; 1993 Jun 19; 341(8860):1603. PubMed ID: 8099684
    [No Abstract] [Full Text] [Related]

  • 30. [Treatment of hyaline membrane disease by administration of exogenous surfactant].
    Bonte F, Dehan M, de Fontanges A, Lindenbaum A, Perret L, Puisieux F.
    Arch Fr Pediatr; 1985 May 19; 42(5):397-402. PubMed ID: 3907577
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Normal and pathological anatomy of the lung in premature babies and in the so-called "hyaline membrane disease"].
    Lauweryns JM.
    Verh K Vlaam Acad Geneeskd Belg; 1972 May 19; 34(3):233-339. PubMed ID: 4605817
    [No Abstract] [Full Text] [Related]

  • 35. Hyaline membrane disease (HMD) therapy in Latin America: impact of exogenous surfactant administration on newborn survival, morbidity and use of resources.
    Rossello JD, Hayward PE, Martell M, Del Barco M, Margotto P, Grandzoto J, Bastida J, Peña J, Villanueva D.
    J Perinat Med; 1997 May 19; 25(3):280-7. PubMed ID: 9288665
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Exogenous surfactant therapy in hyaline membrane disease.
    Gitlin JD, Parad R, Taeusch HW.
    Semin Perinatol; 1984 Oct 19; 8(4):272-82. PubMed ID: 6387924
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.